Skip to main content

Table 2 Dengue antibody GMTs and seropositivity status in the “standard” dengue vaccination schedule (Group 1) versus the “compressed” dengue vaccination schedule (Group 2)

From: Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

Time point Group 1 (N = 117) Group 2 (N = 119)
n GMT (95% CI) Seropositive, % (95% CI) n GMT (95% CI) Seropositive, % (95% CI)
Serotype 1
 Baseline 117 5.38 (4.85–5.96) 1.7 (0.2–6.0) 119 5.13 (4.98–5.28) 2.5 (0.5–7.2)
 28 days post-dose 3 93 14.8 (11.3–19.4) 52.7 (42.1–63.1) 108 15.9 (12.6–20.0) 56.5 (46.6–66.0)
 6 months post-dose 3 88 13.3 (10.2–17.4) 47.7 (37.0–58.6) 104 9.01 (7.54–10.8) 32.7 (23.8–42.6)
Serotype 2
 Baseline 117 5.19 (4.82–5.58) 0.9 (0.0–4.7) 119 5.22 (4.96–5.50) 2.5 (0.5–7.2)
 28 days post-dose 3 94 51.2 (38.2–68.6) 84.0 (75.0–90.8) 108 59.9 (45.8–78.4) 88.0 (80.3–93.4)
 6 months post-dose 3 88 45.6 (31.6–65.6) 75.0 (64.6–83.6) 104 38.7 (29.5–50.8) 80.8 (71.9–87.8)
Serotype 3
 Baseline 117 5.32 (4.94–5.73) 2.6 (0.5–7.3) 119 5.28 (5.03–5.55) 4.2 (1.4–9.5)
 28 days post-dose 3 94 45.7 (35.0–59.8) 85.1 (76.3–91.6) 107 59.3 (47.0–74.7) 90.7 (83.5–95.4)
 6 months post-dose 3 88 30.2 (22.8–40.2) 79.5 (69.6–87.4) 104 34.5 (27.5–43.3) 80.8 (71.9–87.8)
Serotype 4
 Baseline 117 5.78 (5.16–6.48) 6.8 (3.0–13.0) 119 5.11 (4.90–5.33) 0.8 (0.0–4.6)
 28 days post-dose 3 94 66.8 (50.9–87.8) 88.3 (80.0–94.0) 107 83.1 (61.4–112.0) 86.0 (77.9–91.9)
 6-months post-dose 3 88 74.8 (54.9–102.0) 86.4 (77.4–92.8) 104 41.7 (31.2–55.9) 74.0 (64.5–82.1)
≥ 3 serotypes
 Baseline 117 NA 0.9 (0.0–4.7) 119 NA 0.8 (0.0–4.6)
 28 days post-dose 3 94 NA 73.4 (63.3–82.0) 108 NA 82.4 (73.9–89.1)
 6-months post-dose 3 88 NA 64.8 (53.9–74.7) 104 NA 58.7 (48.6–68.2)
All 4 serotypes
 Baseline 117 NA 0.9 (0.0–4.7) 119 NA 0.8 (0.0–4.6)
 Post-dose 3 94 NA 50.0 (39.5–60.5) 108 NA 42.6 (33.1–52.5)
 6-months post-dose 3 88 NA 43.2 (32.7–54.2) 104 NA 26.9 (18.7–36.5)
  1. Seropositive defined as antibody titres ≥10 (1/dil) against each serotype, and against at least 3 or all 4 serotypes with the parental dengue virus strain
  2. GMT geometric mean titre, n number of participants with available data for endpoint, NA not applicable